GC Biopharma has developed a technology platform capable of precisely analyzing how mRNA vaccines degrade when exposed to temperature fluctuations, oxidation, and physical agitation.
The South Korean biopharmaceutical company announced on August 7 that its research into the physicochemical stability and degradation patterns of mRNA-lipid nanoparticle (LNP) vaccines has been published in the international scientific journal Pharmaceutical Research.
mRNA vaccines work by encapsulating delicate genetic instructions inside lipid nanoparticles, which shield the mRNA from premature breakdown and transport it safely into host cells to produce target proteins. However, both the mRNA strands and their protective lipid envelopes are highly vulnerable to environmental degradation. Damage sustained during manufacturing, cold-chain storage, or distribution can compromise vaccine quality and clinical efficacy, making rigorous analytical monitoring essential.
Simulating Supply Chain Stress Through Forced Degradation
To replicate the physical and chemical stresses vaccines encounter throughout distribution, storage, and administration, GC Biopharma researchers conducted a comprehensive "forced degradation study." The team systematically subjected mRNA-LNP formulations to heat, oxidation, hydrolysis, and mechanical shaking.
Using a sophisticated multi-method analytical approach, researchers examined how these environmental stressors altered mRNA purity and nanoparticle structure. Liquid chromatography and capillary electrophoresis were utilized to measure mRNA integrity and degradation. Ultra-high-performance liquid chromatography tracked changes in LNP lipid composition, while cryogenic transmission electron microscopy (Cryo-TEM) captured real-time shifts in nanoparticle morphology. Mass spectrometry (LC-MS/MS) was also deployed to identify trace impurities and degradation products.
Crucially, the team correlated these structural and chemical shifts with the vaccine's functional ability to express target proteins inside cells, creating an end-to-end quality evaluation model.
Standardizing Quality Control for Commercial mRNA Pipelines
The development comes as international health authorities, including the World Health Organization (WHO), work to establish standardized manufacturing and quality-control guidelines for mRNA-based products—a relatively new therapeutic class with evolving regulatory benchmarks.
GC Biopharma plans to integrate this analytical platform across its research and development pipeline—including its ongoing COVID-19 mRNA vaccine program—to refine manufacturing processes, control impurities, and ensure batch-to-batch consistency.
"This study clarifies the relationship between specific quality attributes and degradation mechanisms while proving the value of an integrated, multi-technique stability assessment strategy," said Hong Jung-woon, head of the R&D QM Unit at GC Biopharma. "It offers a reliable benchmark for ensuring quality and consistency as mRNA therapeutics advance toward commercialization."
